At Investor Conferences


Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

MorphoSys AG. (3/9/16). "Press Release: MorphoSys to Present at Upcoming Investor Conferences".

Region Region Paris
  Country France
Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Organisation 2 Leerink Partners LLC
  Today SVB Leerink LLC
Products Product Oddo Biotech / Medtech Forum 2016 Paris
  Product 2 Kempen & Co Healthcare & Life Sciences Conference 2016 Amsterdam
Index term Index term  MorphoSys–Oddo: investor conference, 201603 supply service MorphoSys presents at Oddo Biotech/Medtech Forum in Paris
Persons Person Schottelius, Arndt (Kymab 201806 EVP RnD before MorphoSys 200812–201701 Chief Developm Officer before Genentech)
  Person 2 Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

Leerink Partners Annual Emerging Biotech Conference

Date: March 10, 2016

Venue: Snowbird, UT, USA

Presenter: Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG

Oddo Biotech / Medtech Forum

Date: March 31, 2016

Venue: Paris, France

Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

9th Kempen & Co Life Sciences Conference

Date: April 7, 2016

Venue: Amsterdam, the Netherlands

Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

A PDF version of all presentations will be provided at

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR
Alexandra Goller

Senior Manager Corporate Communications & IR
Jochen Orlowski

Associate Director Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

Record changed: 2017-07-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for MorphoSys (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top